123 related articles for article (PubMed ID: 20191586)
1. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
2. Comments on Initial experience with teriparatide in the United States.
Harper KD; Krege JH; Marcus R; Mitlak BH
Curr Med Res Opin; 2006 Oct; 22(10):1927. PubMed ID: 17022851
[No Abstract] [Full Text] [Related]
3. Osteosarcoma and teriparatide?
Harper KD; Krege JH; Marcus R; Mitlak BH
J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
[No Abstract] [Full Text] [Related]
4. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
5. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
6. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
7. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis.
Tashjian AH; Gagel RF
J Bone Miner Res; 2006 Mar; 21(3):354-65. PubMed ID: 16491282
[No Abstract] [Full Text] [Related]
8. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
9. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
10. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
12. Initial experience with teriparatide in the United States.
Gold DT; Pantos BS; Masica DN; Misurski DA; Marcus R
Curr Med Res Opin; 2006 Apr; 22(4):703-8. PubMed ID: 16684431
[TBL] [Abstract][Full Text] [Related]
13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide: new indication. During corticosteroid therapy: no fewer clinical fractures. Unnecessarily inconvenient.
Prescrire Int; 2009 Aug; 18(102):159. PubMed ID: 19743573
[No Abstract] [Full Text] [Related]
15. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study.
Gilsenan A; Midkiff K; Harris D; Kellier-Steele N; McSorley D; Andrews EB
J Bone Miner Res; 2021 Feb; 36(2):244-251. PubMed ID: 32990990
[TBL] [Abstract][Full Text] [Related]
17. Treatment of osteoporosis with Teriparatide rhPTH(1-34).
San Martin J
J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):406. PubMed ID: 15758281
[No Abstract] [Full Text] [Related]
18. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
[TBL] [Abstract][Full Text] [Related]
19. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
20. Nonuremic calciphylaxis in a patient with rheumatoid arthritis and osteoporosis treated with teriparatide.
Dominguez AR; Goldman SE
J Am Acad Dermatol; 2014 Feb; 70(2):e41-2. PubMed ID: 24438979
[No Abstract] [Full Text] [Related]
[Next] [New Search]